TuHURA Biosciences (HURA) Other Accumulated Expenses (2023 - 2024)
TuHURA Biosciences' (HURA) quarterly Other Accumulated Expenses came in at $50000.0 in Q3 2024, down 85.21% year-on-year from $338000.0 in Q4 2023, and down 3.85% quarter-over-quarter from $52000.0 in Q2 2024.
TuHURA Biosciences (HURA) Other Accumulated Expenses (2023 - 2024) Analysis & Trends
TuHURA Biosciences' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $50000.0 for Q3 2024.
- On a quarterly basis, Other Accumulated Expenses fell 85.21% year-over-year to $50000.0 in Q3 2024; TTM through Sep 2024 was $50000.0, a 85.21% decrease from a year earlier, with the FY2024 full-year figure at $52000.0, down 82.55% from the prior year.
- Other Accumulated Expenses eased to $50000.0 in Q3 2024 per HURA's latest filing, from $52000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $338000.0 in Q3 2023 and bottomed at $50000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | TuHURA Biosciences | 132.62 Mn | 132.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | 338,000.00 |
| Jun 30, 2023 | 298,000.00 |